ER+/HER2- breast cancer
Onco
Daily
Twitter
Facebook
Youtube
RSS Feed
Linkedin
Facebook
RSS
Twitter
Youtube
Linkedin
May, 2024
May 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
« Apr
ER+/HER2- breast cancer
Apr 25, 2024, 21:06 |
Drugs
Piotr Wysocki: Datopotamab deruxtecan – another anti-TROP2 conjugate demonstrating activity in advanced ER+/HER2- and triple-negative breast cancer patients
Piotr Wysocki recently shared on LinkedIn: "Datopotamab deruxtecan – a novel anti-TROP2 conjugate demonstrates activity…
Mar 27, 2024, 10:07 |
Insight
Piotr Wysocki: No benefit of continuing CDK4/6i beyond progression in advanced ER+/HER2- breast cancer
Piotr Wysocki, Professor of Medicine and Head of the Department of Oncology at Jagiellonian University…
Mar 14, 2024, 19:28 |
Drugs
François-Clément Bidard: A prospective study to document the efficacy of the combo Fulvestrant+Everolimus
Erika Hamilton, Director of Breast Cancer and Gynecologic Cancer Research at Sarah Cannon Research Institute, shared…
Feb 9, 2024, 17:30 |
Blog
Chris Boshoff: The U.S. FDA has granted Fast Track designation for our investigational treatment for ER+/HER2- breast cancer
Chris Boshoff, Chief Oncology Officer and Executive Vice President at Pfizer, posted on LinkedIn: "I’m…
All:
4
Posts:
1 - 10
OncoInfluencers: Dialogue with Rob Pieters, hosted by Shushan Hovsepyan
10 Most Promising Cancer Drugs Not Yet Approved: Solid Tumors - 2024 edition by OncoDaily
Elie G. Dib: Excited to share the results of the TAPUR study
OncoInfluencers: Dialogue with Fadlo R. Khuri, hosted by Gevorg Tamamyan
Cedars-Sinai is co-chairing a special AACR conference on transforming the field of Bladder Cancer on May 17-20
Facebook
RSS Feed
Twitter
Linkedin
Youtube